Perrigo Reports Record Third Quarter (payment of $8.5 million. The decrease in...)

Perrigo Reports Record Third Quarter

Date:5/7/2009

payment of $8.5 million. The decrease in net sales was also due to an $8.2 million reduction in non-product revenue, as well as pricing pressures due to continued competition in the marketplace for generic drugs. These decreases were partially offset by new product sales of approximately $11.0 million, along with an increase in sales volumes on the Company's existing portfolio of products of approximately $7.0 million.

On March 17, 2009, the Company announced that its partner Cobrek Pharmaceuticals, Inc. (Cobrek) had filed an Abbreviated New Drug Application (ANDA) for Clindamycin Phosphate Foam 1%, a generic version of Evoclin(R) Foam 1%. The Company believes that Cobrek is the first to file an ANDA with a Paragraph IV certification against Evoclin(R). Evoclin(R) (clindamycin phosphate) Foam 1% is a topical antibiotic indicated for topical application in the treatment of acne vulgaris, and had sales of approximately $44 million for the 12 months ended January 2009, as measured by Wolters Kluwer Health.

API

The API segment reported third quarter net sales of $31.0 million compared with $37.8 million a year ago. The decrease was due primarily to the absence of a one-time $4.9 million accrual reversal related to a long standing customer contract negotiation recognized in fiscal 2008, along with approximately $2.0 million resulting from unfavorable changes in foreign currency exchange rates. Operating income was $4.3 million, compared with $6.0 million last year, reflecting the aforementioned accrual reversal, as well as unfavorable foreign currency exchange rate changes, partially offset by favorable contributions from new products, pricing improvements and lower operating expenses.

For the first nine months of fiscal year 2009, net sales decreased 13% compared to fiscal 2008. This decrease was due primarily to a decline of approximately $16.7 million in sales of three key products, the abse
'/>"/>

SOURCE Perrigo Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Related medicine news :

1. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service
2. Perrigo Company to Host Analyst Meeting on September 18, 2007
3. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
4. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
5. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
6. Perrigo Company Will Release First Quarter Fiscal 2008 Results on November 1, 2007
7. Perrigo Company Announces Dividend Increase
8. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
9. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
10. Perrigo Acquires UK OTC Store Brand Supplier
11. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend

Post Your Comments:

(Date:5/21/2013)... (PRWEB) May 21, 2013 DISCcert has ... showing how to use 17 DISC applications at the ... a natural progression. , The July 25 & 26th ... top 17 ways of applying DISC. The time-tested, proven ... graduates. The user-friendly DISC training materials ; ...

(Date:5/21/2013)... 21, 2013) Prostaglandin analogues (PGAs), drugs which lower ... for people with glaucoma, but their use is not ... vision, dryness, changes in eye color and other side ... drugs also cause upper and lower eyelid drooping and ... are described in PLOS ONE . , Researchers ...

(Date:5/21/2013)... Mecklenburg EMS Agency (Medic) and ... free Community Wellness Fair to educate the public on health ... held on Wednesday, May 22, 2013 from 4:00 pm until ... Old Mallard Creek Road, Charlotte, NC 29262). , ... the Mecklenburg County Department of Social Services are ...

(Date:5/21/2013)... 2013, Paris, France: One-year results from SOURCE XT ... (TAVI) registries to-date reported today at EuroPCR 2013 ... high rates of device success for all access approaches, ... Post-Approval Study followed up 2688 consecutively enrolled patients (mean ... heart valve at 93 centres in 17 countries between ...

(Date:5/21/2013)... Angeles, CA (PRWEB) May 21, 2013 According ... “Time to Rethink the Use of Botox,” Botox ... world since their approval in 2002 (Go to goo.gl/8iYbD). Although ... become quite popular with men. The injection makes facial wrinkles ... single Botox injection last for about three months. This means ...

Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4 Health News:Glaucoma drug can cause droopy eyelids 2 Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2 Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2

[0] DISCcert Offers 17 Applications in Coming DISC Certification [0] Glaucoma drug can cause droopy eyelids [0] Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives [0] Post-approval TAVI registry shows high rates of device success at 1 year [0] Botox – Is the World’s Most Popular Cosmetic Procedure Safe?

... Minority Quality Forum Launches First U.S. HIV/AIDS Atlas , ... today launched a groundbreaking HIV/AIDS Atlas ( http://www.MapHIV.org ... epidemic in communities across the United States. The Atlas ... location for the first time, painting a comprehensive picture of ...

... Perfect Time for Fitness! , , LOS ANGELES, June 22 ... in the park or along the beach. Now a brand new ... fitness equipment on wheels, but with a unique design to allow ... a new concept of fitness, will be introduced to California starting ...

... , DentaBurst(TM) delivers an on-the-go oral care solution to ... NEW YORK, June 22 Crown Consumer Brands today ... the original proven technology will remain intact, an improved, ... will accompany this highly anticipated re-launch. , ...

... MUSCLEPHARM(R) LLC, the rising star of the Sports Nutrition ... through each of Vitamin Shoppe,s 400+ locations nationwide. , ... launch of our entire line of products," MUSCLEPHARM president ... athletes in nearly every neighborhood across the nation! Vitamin ...

... Transcend Medical, Inc., an ophthalmic device company dedicated ... announced today that it has closed a $35 million ... of its Transcend CyPass(TM) System, a novel proprietary system ... Lead investor HLM Venture Partners, along with other new ...

... Magnetic Resonance Center of the University Children,s Hospital ... in MR-guided, non-invasive neurosurgery. Ten patients have been ... ultrasound. This fully non-invasive procedure opens new horizons ... brain disorders. In the context of a ...

Cached Medicine News:Health News:MapHIV.org Shows 18% of Georgia's Counties are Seriously Impacted by HIV 2 Health News:MapHIV.org Shows 18% of Georgia's Counties are Seriously Impacted by HIV 3 Health News:Pumgo Fitness Scooter Will Highlight Venice Beach This Summer 2 Health News:Crown Consumer Brands Re-Launches DentaBurst(TM) Freshening Teeth Cleaners 2 Health News:MUSCLEPHARM Products Hit Vitamin Shoppe Shelves With a Bang! 2 Health News:Transcend Medical Raises $35 Million Series B Round Towards Development of Novel Glaucoma Treatment 2 Health News:Successful neurosurgery with transcranial MR-guided high-intensity focused ultrasound 2 Health News:Successful neurosurgery with transcranial MR-guided high-intensity focused ultrasound 3

MapHIV.org Shows 18% of Georgia's Counties are Seriously Impacted by HIV Pumgo Fitness Scooter Will Highlight Venice Beach This Summer Crown Consumer Brands Re-Launches DentaBurst(TM) Freshening Teeth Cleaners MUSCLEPHARM Products Hit Vitamin Shoppe Shelves With a Bang!Transcend Medical Raises $35 Million Series B Round Towards Development of Novel Glaucoma Treatment Successful neurosurgery with transcranial MR-guided high-intensity focused ultrasound

(Date:5/21/2013)... , May 21, 2013 Decision Resources, ... advisory firms for pharmaceutical and healthcare issues, ... agent on key efficacy endpoints, including overall ... the most influence over surveyed U.S. and ... (HR-) positive, HER2-negative breast cancer. The two ...

(Date:5/21/2013)... NORTH BRUNSWICK, N.J. , May 21, 2013 /PRNewswire/ ... artificial tissue constructs and microfluidic cell-based assay platforms, today ... , PhD, DABT to the Company,s Board of ... of Preclinical Development of the Schering-Plough Research Institute ("SPRI"), ... prior to its acquisition by Merck & Co. in ...

(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Technologies for Optical Coherence Tomography (OCT) ... STUDY OBJECTIVES ... study is to offer synopsis of the ...

[0] Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer [0] Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors [0] Global Markets and Technologies for Optical Coherence Tomography (OCT)

... 19, 2011 Varian Medical Systems, Inc., ... Inc., today announced they have signed a definitive agreement ... developer and supplier of specialized products and software for ... radiotherapy. The acquisition, which is anticipated to close in ...

... Sept. 19, 2011 VIDA Diagnostics, a leading developer ... company has achieved International Organization for Standardization (ISO 13485) ... The CE certification permits VIDA to sell Apollo for ... Switzerland. Apollo currently has FDA 510(k) approval for clinical ...

Cached Medicine Technology:Varian Medical Systems Signs Agreement to Acquire Calypso Medical Technologies; Acquisition Adds Products for Tracking Tumor Motion During Radiosurgery and Radiotherapy 2 Varian Medical Systems Signs Agreement to Acquire Calypso Medical Technologies; Acquisition Adds Products for Tracking Tumor Motion During Radiosurgery and Radiotherapy 3 Varian Medical Systems Signs Agreement to Acquire Calypso Medical Technologies; Acquisition Adds Products for Tracking Tumor Motion During Radiosurgery and Radiotherapy 4 Varian Medical Systems Signs Agreement to Acquire Calypso Medical Technologies; Acquisition Adds Products for Tracking Tumor Motion During Radiosurgery and Radiotherapy 5

Varian Medical Systems Signs Agreement to Acquire Calypso Medical Technologies; Acquisition Adds Products for Tracking Tumor Motion During Radiosurgery and Radiotherapy VIDA Diagnostics Earns ISO 13485 and CE Certifications

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

Medicine Products:

Reducing Substances, Fecal RBC Fecal Rapid Plasma Reagin (RPR with Reflex to Fluorescent Treponemal Antibody, IgG Confirmation Rabies Antibody(Vaccine Response)